Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialisation of products for the treatment of central nervous system disorders, announced that a Hetlioz patent, number 9,060,995 ('995 patent), is now listed in the US Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

The '995 patent was issued by the United States Patent and Trademark Office on June 23, 2015 and expires in January 2033. Prior to this newly listed '995 patent, the Hetlioz Orange Book listed patents were the US composition of matter '529 patent and the '492 patent, expected to expire in December 2022 (assuming receipt of the five-year patent term extension under the Hatch-Waxman Act) and January 2033, respectively.